Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses
Weina Sun, Yonghong Liu, Fatima Amanat, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Intranasal COVID-19 vaccines: From bench to bed
Aqu Alu, Li Chen, Lei Hong, et al.
EBioMedicine (2022) Vol. 76, pp. 103841-103841
Open Access | Times Cited: 210
SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals
Kaori Sano, Disha Bhavsar, Gagandeep Singh, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 115
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases
Shen Wang, Bo Liang, Weiqi Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 87
Mucosal vaccines for SARS-CoV-2: triumph of hope over experience
Devaki Pilapitiya, Adam K. Wheatley, Hyon‐Xhi Tan
EBioMedicine (2023) Vol. 92, pp. 104585-104585
Open Access | Times Cited: 47
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
Lynda Coughlan, Eric J. Kremer, Dmitry M. Shayakhmetov
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1822-1849
Open Access | Times Cited: 44
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial
Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
EClinicalMedicine (2022) Vol. 45, pp. 101323-101323
Open Access | Times Cited: 44
SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern
Mijia Lu, Michelle Chamblee, Yuexiu Zhang, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 35
Open Access | Times Cited: 44
The role of vaccines in the COVID-19 pandemic: what have we learned?
Florian Krammer
Seminars in Immunopathology (2023) Vol. 45, Iss. 4-6, pp. 451-468
Open Access | Times Cited: 38
Advances in intranasal vaccine delivery: A promising non-invasive route of immunization
Eleni Kehagia, Paraskevi Papakyriakopoulou, Georgia Valsami
Vaccine (2023) Vol. 41, Iss. 24, pp. 3589-3603
Open Access | Times Cited: 37
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
Samuel Ponce‐de‐León, Martha Torres, Luis Enrique Soto-Ramírez, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 25
Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens
Farokh Dotiwala, Arun Kumar Upadhyay
Vaccines (2023) Vol. 11, Iss. 10, pp. 1585-1585
Open Access | Times Cited: 24
Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges
Bryce M. Warner, Jacob G. E. Yates, Robert Vendramelli, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam
Anh Duc Dang, Vũ Đình Thiểm, Ha Hai Vu, et al.
Vaccine (2022) Vol. 40, Iss. 26, pp. 3621-3632
Open Access | Times Cited: 29
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges
Ziyi Bai, Dandan Wan, Tianxia Lan, et al.
ACS Nano (2024) Vol. 18, Iss. 36, pp. 24650-24681
Open Access | Times Cited: 6
Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice
Stefan Slamanig, Irene González‐Domínguez, Lauren A Chang, et al.
EBioMedicine (2024) Vol. 105, pp. 105185-105185
Open Access | Times Cited: 5
Interactions of Viral Pathogenic Waste with Clays for Containment Applications
Himanshu Yadav, Tadikonda Venkata Bharat, Sachin Kumar
(2025), pp. 143-152
Closed Access
Development of Nasal Vaccines and the Associated Challenges
Xuanxuan Nian, Jiayou Zhang, Shihe Huang, et al.
Pharmaceutics (2022) Vol. 14, Iss. 10, pp. 1983-1983
Open Access | Times Cited: 26
A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine
Jingen Zhu, Swati Jain, Jian Sha, et al.
mBio (2022) Vol. 13, Iss. 4
Open Access | Times Cited: 25
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico
Samuel Ponce‐de‐León, Martha Torres, Luis Enrique Soto-Ramírez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 23
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination
Juan Manuel Carreño, Ariel Raskin, Gagandeep Singh, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 683
Open Access | Times Cited: 14
Evaluation and deployment of isotype-specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults
Amy Thomas, Elizabeth Oliver, Holly E. Baum, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 14
Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants
Siriruk Changrob, Peter Halfmann, Hejun Liu, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 8
Open Access | Times Cited: 12
Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use
Julia Puppin Chaves Fulber, Amine Kamen
Viruses (2022) Vol. 14, Iss. 5, pp. 975-975
Open Access | Times Cited: 21
Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice
Irene González‐Domínguez, José Luis Martínez, Stefan Slamanig, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 21
Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination
Fatima Amanat, Jordan Clark, Juan Manuel Carreño, et al.
Journal of Virology (2023) Vol. 97, Iss. 3
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top